Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial-Reference-Cited by-同舟云学术

Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial

Published:2019-11 Issue:6 Volume:2 Page:677-684
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Armstrong Andrew J.,Lin Ping,Higano Celestia S.,Iversen Peter,Sternberg Cora N.,Tombal Bertrand,Phung De,Parli Teresa,Krivoshik Andrew,Beer Tomasz M.

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference19 articles.

1. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

2. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial

3. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer;Armstrong;J Clin Oncol,2007

4. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer;Halabi;J Clin Oncol,2014

5. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial;European Urology;2024-09

2. Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-29

3. PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC);Clinical and Translational Oncology;2024-07-29

4. Abiraterone Acetate Versus Enzalutamide Against Chemo-Naïve Castration-Resistant Prostate Cancer With Full-Dose Induction;Cureus;2024-07-10

5. Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-naïve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real world;International Urology and Nephrology;2024-06-24